Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Effects of an Ex Vivo Pediatric Extracorporeal Membrane Oxygenation Circuit on the Sequestration of Mycophenolate Mofetil, Tacrolimus, Hydromorphone, and Fentanyl.

Heith CS, Hansen LA, Bakken RM, Ritter SL, Long BR, Hume JR, Zhang L, Amundsen DB, Steiner ME, Fischer GA.

J Pediatr Pharmacol Ther. 2019 Jul-Aug;24(4):290-295. doi: 10.5863/1551-6776-24.4.290.

2.

Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.

Wec AZ, Bornholdt ZA, He S, Herbert AS, Goodwin E, Wirchnianski AS, Gunn BM, Zhang Z, Zhu W, Liu G, Abelson DM, Moyer CL, Jangra RK, James RM, Bakken RR, Bohorova N, Bohorov O, Kim DH, Pauly MH, Velasco J, Bortz RH 3rd, Whaley KJ, Goldstein T, Anthony SJ, Alter G, Walker LM, Dye JM, Zeitlin L, Qiu X, Chandran K.

Cell Host Microbe. 2019 Jan 9;25(1):39-48.e5. doi: 10.1016/j.chom.2018.12.004.

PMID:
30629917
3.

Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail.

Froude JW, Herbert AS, Pelat T, Miethe S, Zak SE, Brannan JM, Bakken RR, Steiner AR, Yin G, Hallam TJ, Sato AK, Hust M, Thullier P, Dye JM.

Viruses. 2018 May 26;10(6). pii: E286. doi: 10.3390/v10060286.

4.

Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.

Nyakatura EK, Zak SE, Wec AZ, Hofmann D, Shulenin S, Bakken RR, Aman MJ, Chandran K, Dye JM, Lai JR.

J Biol Chem. 2018 Apr 20;293(16):6201-6211. doi: 10.1074/jbc.RA117.001627. Epub 2018 Mar 2.

5.

Mechanistic and Fc requirements for inhibition of Sudan virus entry and in vivo protection by a synthetic antibody.

Hofmann D, Zak SE, Nyakatura EK, Mittler E, Bakken RR, Chandran K, Dye JM, Lai JR.

Immunol Lett. 2017 Oct;190:289-295. doi: 10.1016/j.imlet.2017.09.002. Epub 2017 Sep 8.

6.

Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Lennemann NJ, Herbert AS, Brouillette R, Rhein B, Bakken RA, Perschbacher KJ, Cooney AL, Miller-Hunt CL, Ten Eyck P, Biggins J, Olinger G, Dye JM, Maury W.

J Virol. 2017 Aug 10;91(17). pii: e00479-17. doi: 10.1128/JVI.00479-17. Print 2017 Sep 1.

7.

Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality.

Dias A, Al-Kali A, Van Dyke D, Niederwieser D, Vucinic V, Lemke J, Muller C, Schwind S, Teichmann AC, Bakken R, Burns LJ, Litzow M.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1582-1587. doi: 10.1016/j.bbmt.2017.05.019. Epub 2017 May 23.

8.

Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.

Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, de La Vega MA, Zhu W, Bakken RR, Goodwin E, Turner HL, Jangra RK, Zeitlin L, Qiu X, Lai JR, Walker LM, Ward AB, Dye JM, Chandran K, Bornholdt ZA.

Cell. 2017 May 18;169(5):878-890.e15. doi: 10.1016/j.cell.2017.04.037.

9.

Generation and characterization of protective antibodies to Marburg virus.

Froude JW, Pelat T, Miethe S, Zak SE, Wec AZ, Chandran K, Brannan JM, Bakken RR, Hust M, Thullier P, Dye JM.

MAbs. 2017 May/Jun;9(4):696-703. doi: 10.1080/19420862.2017.1299848. Epub 2017 Mar 13.

10.

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects.

Bekerman E, Neveu G, Shulla A, Brannan J, Pu SY, Wang S, Xiao F, Barouch-Bentov R, Bakken RR, Mateo R, Govero J, Nagamine CM, Diamond MS, De Jonghe S, Herdewijn P, Dye JM, Randall G, Einav S.

J Clin Invest. 2017 Apr 3;127(4):1338-1352. doi: 10.1172/JCI89857. Epub 2017 Feb 27.

11.

Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice.

Lehrer AT, Wong TS, Lieberman MM, Humphreys T, Clements DE, Bakken RR, Hart MK, Pratt WD, Dye JM.

Vaccine. 2018 May 24;36(22):3090-3100. doi: 10.1016/j.vaccine.2017.01.068. Epub 2017 Feb 16.

PMID:
28216187
12.

BLR1 and FCGR1A transcripts in peripheral blood associate with the extent of intrathoracic tuberculosis in children and predict treatment outcome.

Jenum S, Bakken R, Dhanasekaran S, Mukherjee A, Lodha R, Singh S, Singh V, Haks MC, Ottenhoff TH, Kabra SK, Doherty TM, Ritz C, Grewal HM.

Sci Rep. 2016 Dec 12;6:38841. doi: 10.1038/srep38841.

13.

A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses.

Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE Jr, Aman MJ, Dye JM, Lai JR, Chandran K.

Science. 2016 Oct 21;354(6310):350-354. Epub 2016 Sep 8.

14.

1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus.

Gupta P, Sharma A, Spurgers KB, Bakken RR, Eccleston LT, Cohen JW, Honnold SP, Glass PJ, Maheshwari RK.

Vaccine. 2016 May 27;34(25):2762-5. doi: 10.1016/j.vaccine.2016.04.049. Epub 2016 Apr 26.

PMID:
27129427
15.

Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.

Dye JM, Wu H, Hooper JW, Khurana S, Kuehne AI, Coyle EM, Ortiz RA, Fuentes S, Herbert AS, Golding H, Bakken RA, Brannan JM, Kwilas SA, Sullivan EJ, Luke TC, Smith G, Glenn G, Li W, Ye L, Yang C, Compans RW, Tripp RA, Jiao JA.

Sci Rep. 2016 Apr 25;6:24897. doi: 10.1038/srep24897.

16.

Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.

Frei JC, Nyakatura EK, Zak SE, Bakken RR, Chandran K, Dye JM, Lai JR.

Sci Rep. 2016 Jan 13;6:19193. doi: 10.1038/srep19193.

17.

Eastern equine encephalitis virus in mice II: pathogenesis is dependent on route of exposure.

Honnold SP, Mossel EC, Bakken RR, Lind CM, Cohen JW, Eccleston LT, Spurgers KB, Erwin-Cohen R, Glass PJ, Maheshwari RK.

Virol J. 2015 Sep 30;12:154. doi: 10.1186/s12985-015-0385-2.

18.

Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

Bounds CE, Kwilas SA, Kuehne AI, Brannan JM, Bakken RR, Dye JM, Hooper JW, Dupuy LC, Ellefsen B, Hannaman D, Wu H, Jiao JA, Sullivan EJ, Schmaljohn CS.

PLoS One. 2015 Sep 30;10(9):e0137786. doi: 10.1371/journal.pone.0137786. eCollection 2015.

19.

Eastern equine encephalitis virus in mice I: clinical course and outcome are dependent on route of exposure.

Honnold SP, Mossel EC, Bakken RR, Fisher D, Lind CM, Cohen JW, Eccleston LT, Spurgers KB, Erwin-Cohen R, Bradfute SB, Maheshwari RK, Glass PJ.

Virol J. 2015 Sep 29;12:152. doi: 10.1186/s12985-015-0386-1.

20.

[Who should become a physician?].

Bakken R, Valestrand EA.

Tidsskr Nor Laegeforen. 2015 Aug 11;135(14):1235. doi: 10.4045/tidsskr.15.0672. eCollection 2015 Aug 11. Norwegian. No abstract available.

21.

Niemann-pick C1 is essential for ebolavirus replication and pathogenesis in vivo.

Herbert AS, Davidson C, Kuehne AI, Bakken R, Braigen SZ, Gunn KE, Whelan SP, Brummelkamp TR, Twenhafel NA, Chandran K, Walkley SU, Dye JM.

MBio. 2015 May 26;6(3):e00565-15. doi: 10.1128/mBio.00565-15.

22.

Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.

Brannan JM, Froude JW, Prugar LI, Bakken RR, Zak SE, Daye SP, Wilhelmsen CE, Dye JM.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S282-94. doi: 10.1093/infdis/jiv215. Epub 2015 May 4.

PMID:
25943199
23.

Whole genome sequencing of clinical isolates of Giardia lamblia.

Hanevik K, Bakken R, Brattbakk HR, Saghaug CS, Langeland N.

Clin Microbiol Infect. 2015 Feb;21(2):192.e1-3. doi: 10.1016/j.cmi.2014.08.014. Epub 2014 Oct 29.

24.

Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Reed DS, Glass PJ, Bakken RR, Barth JF, Lind CM, da Silva L, Hart MK, Rayner J, Alterson K, Custer M, Dudek J, Owens G, Kamrud KI, Parker MD, Smith J.

J Virol. 2014 Oct;88(20):12077-86. doi: 10.1128/JVI.01406-14. Epub 2014 Aug 13.

25.

Second generation inactivated eastern equine encephalitis virus vaccine candidates protect mice against a lethal aerosol challenge.

Honnold SP, Bakken RR, Fisher D, Lind CM, Cohen JW, Eccleston LT, Spurgers KB, Maheshwari RK, Glass PJ.

PLoS One. 2014 Aug 12;9(8):e104708. doi: 10.1371/journal.pone.0104708. eCollection 2014.

26.

Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM.

J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13.

27.

Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage.

Fenimore PW, Muhammad MA, Fischer WM, Foley BT, Bakken RR, Thurmond JR, Yusim K, Yoon H, Parker M, Hart MK, Dye JM, Korber B, Kuiken C.

PLoS One. 2012;7(10):e44769. doi: 10.1371/journal.pone.0044769. Epub 2012 Oct 3.

28.

Ectopic pregnancy after levonorgestrel emergency contraception.

Kozinszky Z, Bakken RT, Lieng M.

Contraception. 2011 Mar;83(3):281-3. doi: 10.1016/j.contraception.2010.08.008. Epub 2010 Oct 29.

PMID:
21310292
29.

High-resolution functional mapping of the venezuelan equine encephalitis virus genome by insertional mutagenesis and massively parallel sequencing.

Beitzel BF, Bakken RR, Smith JM, Schmaljohn CS.

PLoS Pathog. 2010 Oct 14;6(10):e1001146. doi: 10.1371/journal.ppat.1001146.

30.

Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL.

Vaccine. 2010 Apr 19;28(18):3143-51. doi: 10.1016/j.vaccine.2010.02.056. Epub 2010 Mar 1.

31.

Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.

Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL.

Vaccine. 2010 Jan 22;28(4):1031-40. doi: 10.1016/j.vaccine.2009.10.126. Epub 2009 Nov 13.

32.

Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine.

Martin SS, Bakken RR, Lind CM, Reed DS, Price JL, Koeller CA, Parker MD, Hart MK, Fine DL.

Vaccine. 2009 Nov 16;27(49):6814-23. doi: 10.1016/j.vaccine.2009.09.013. Epub 2009 Sep 15.

33.

Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine.

Dupuy LC, Locher CP, Paidhungat M, Richards MJ, Lind CM, Bakken R, Parker MD, Whalen RG, Schmaljohn CS.

Vaccine. 2009 Jun 24;27(31):4152-60. doi: 10.1016/j.vaccine.2009.04.049. Epub 2009 May 9.

PMID:
19406186
34.

Subjective and objective measures of sleep in children with attention-deficit/hyperactivity disorder.

Owens J, Sangal RB, Sutton VK, Bakken R, Allen AJ, Kelsey D.

Sleep Med. 2009 Apr;10(4):446-56. doi: 10.1016/j.sleep.2008.03.013. Epub 2008 Aug 6.

PMID:
18693137
35.

Effects of atomoxetine on attention-deficit/hyperactivity disorder in clinical pediatric treatment settings: a naturalistic study.

Bakken RJ, Paczkowski M, Kramer HP, Axelson AA, Williams DW, Malcolm SK, Sumner CR, Kelsey DK.

Curr Med Res Opin. 2008 Feb;24(2):449-60. doi: 10.1185/030079908X253627 .

PMID:
18179733
36.

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder.

Geller D, Donnelly C, Lopez F, Rubin R, Newcorn J, Sutton V, Bakken R, Paczkowski M, Kelsey D, Sumner C.

J Am Acad Child Adolesc Psychiatry. 2007 Sep;46(9):1119-1127. doi: 10.1097/chi.0b013e3180ca8385.

PMID:
17712235
37.

Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD.

Adler L, Dietrich A, Reimherr FW, Taylor LV, Sutton VK, Bakken R, Allen AJ, Kelsey D.

Ann Clin Psychiatry. 2006 Apr-Jun;18(2):107-13.

PMID:
16754416
38.

Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.

Olinger GG, Bailey MA, Dye JM, Bakken R, Kuehne A, Kondig J, Wilson J, Hogan RJ, Hart MK.

J Virol. 2005 Nov;79(22):14189-96.

39.

Donor commitment and patient needs.

Bakken R, van Walraven AM, Egeland T; Ethics Working Group of the World Marrow Donor Association.

Bone Marrow Transplant. 2004 Jan;33(2):225-30.

PMID:
14628078
40.

Family characteristics and sexual risk behaviors among black men in the United States.

Bakken RJ, Winter M.

Perspect Sex Reprod Health. 2002 Sep-Oct;34(5):252-8.

PMID:
12392218
41.

Effect of aerobic exercise on tracking performance in elderly people: a pilot study.

Bakken RC, Carey JR, Di Fabio RP, Erlandson TJ, Hake JL, Intihar TW.

Phys Ther. 2001 Dec;81(12):1870-9.

PMID:
11736621
42.

Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice.

Hart MK, Lind C, Bakken R, Robertson M, Tammariello R, Ludwig GV.

Vaccine. 2001 Nov 12;20(3-4):616-22.

PMID:
11672929
43.

Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.

Wilson JA, Bray M, Bakken R, Hart MK.

Virology. 2001 Aug 1;286(2):384-90.

44.

Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate.

Hart MK, Caswell-Stephan K, Bakken R, Tammariello R, Pratt W, Davis N, Johnston RE, Smith J, Steele K.

Vaccine. 2000 Jul 1;18(26):3067-75.

PMID:
10825611
45.

Epitopes involved in antibody-mediated protection from Ebola virus.

Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK.

Science. 2000 Mar 3;287(5458):1664-6.

46.

Household nutrition and health in Poland.

Bakken R, Jezewska-Zychowicz M, Winter M.

Soc Sci Med. 1999 Dec;49(12):1677-87.

PMID:
10574238

Supplemental Content

Loading ...
Support Center